43
Subclinical hypothyroid ism Dr.YASSIN ALSALEH

subclinical hypothyrodism

Embed Size (px)

Citation preview

Page 1: subclinical hypothyrodism

Subclinical hypothyroidism

Dr.YASSIN ALSALEH

Page 2: subclinical hypothyrodism
Page 3: subclinical hypothyrodism
Page 4: subclinical hypothyrodism

CASE SCENARIO• 4 year old child case of chronic

constipation ,obesity found to have abnormal TFT:• TSH :8 high FT4:17 normal • what is the next step???

Page 5: subclinical hypothyrodism

Synonyms • Compensated hypothyroidism.• latent hypothyroidism. • preclinical hypothyroidism. • euthyroid

hyperthyrotropinemia.

Page 6: subclinical hypothyrodism

Introduction• Definition:• SCH is biochemically defined

as (TSH) is above the upper-limit of the statistically defined reference range • while the serum free

thyroxine (FT4) is within its reference range.

TSH↑

FT4 N

Page 7: subclinical hypothyrodism

Laboratory definition• TSH is secreted in a pulsatile manner

and shows diurnal variation.• The levels may vary based on the

time of sampling as well as its relation to food.• TSH is false high In about 0.5 to 5%

of patient samples.

Page 8: subclinical hypothyrodism

Laboratory definition

mildly increased (4.5–10 mIU/l) severely increased (>10 mIU/l)

TSH

Pediatric > one month of age

Page 9: subclinical hypothyrodism

• The prevalence of SCH in the pediatric population is 2%

EPIDEMIOLOGY

Page 10: subclinical hypothyrodism
Page 11: subclinical hypothyrodism

Manifestations• Asymptomatic.

• A goiter is the most common manifestation.

Page 12: subclinical hypothyrodism

• weight gain.• increased cholesterol levels.• impaired growth velocity.• anemia.• sleepiness, weakness.• impaired psychomotor and cognitive

development.

Manifestations

Page 13: subclinical hypothyrodism

etiologycauses

anatomicallythyroidal

others(association)

pathophysiologicalidiopathic

autoimmune

Page 14: subclinical hypothyrodism

Thyroidal Causes• Autoimmune thyroiditis

(HASHIMOTOS) . (most common) 50-80% of cases.• Developmental anomalies

(hypoplasia, hemiagensis). • TSH Resistance syndrome (RTSH).

Page 15: subclinical hypothyrodism

other causes • newborns classified false positive at

congenital hypothyroidism screening .(up to 70%)• SGA . Up to 50% .• Down’s syndrome. up to 32%• William’ syndrome. Up to 31.5%.

Page 16: subclinical hypothyrodism

others• diabetes mellitus (11%).• cystic fibrosis.• celiac disease. • chronic renal failure.

• obesity up to 25%.

Page 17: subclinical hypothyrodism
Page 18: subclinical hypothyrodism

Natural History and Progression

TSH

Normalized 30-40%

>70% if TSH

<10

Overt hypothyroi

dism 1-10% Up to

20% if Autoimm

une

SCH

Page 19: subclinical hypothyrodism

ProgressionNon-autoimmune ‘idiopathic’ SCH

• either discovered on newborn screening or later during childhood.• normalizes in 36–88% of patients

Page 20: subclinical hypothyrodism

Progression• Risk factor for progression to overt

hypothyroidism• Goiter.• TSH levels.• Presence of thryoglobulin antibody. • progressive increase in anti-thyroid

peroxidase (TPO) antibodies .• female sex.• family history of thyroid disorder

Page 21: subclinical hypothyrodism

Therapy

• There is no consensus on therapy of SCH in children.

Page 22: subclinical hypothyrodism

Therapy

NO YES

Page 23: subclinical hypothyrodism

• Studies analyzing height, growth velocity, and puberty did not confirm a negative influence of SH.

• few studies showed beneficial effect on idiopathic short stature and SCH.

Effects of Therapy on Growth velocity

Page 24: subclinical hypothyrodism

• Studies showed improve metabolic control in type 1 diabetics.• improvement in growth velocity.

• Improvement was better in patients with higher TSH at entry.

Effects of Therapy on diabetic patients

Page 25: subclinical hypothyrodism

Therapy in Autoimmune Thyroid Disease

• Prophylactic L-T4 therapy of patients with euthyroid AITD reduces serological markers of autoimmune thyroiditis.• L-T4 therapy might be useful for

stopping progression of the disease.

Page 26: subclinical hypothyrodism

Therapy (goiter)

• L-thyroxine therapy reduce thyroid volume in those patients with goiter.

Page 27: subclinical hypothyrodism

Therapy (obese child)

• hyperthyrotropinemia in obesity is a consequence rather than a cause.

• therefore L-T4 therapy is unnecessary in obese children.

• Patients should be encouraged to implement appropriate diet and exercise programs

Page 28: subclinical hypothyrodism
Page 29: subclinical hypothyrodism

Therapy (migrane)

• children aged between 5 and 15 yrs diagnosed with SH suffered more frequently from the migraines which were also lasting longer.

Page 30: subclinical hypothyrodism

Effects of SCH on Neuropsychological Development

• Neuropsychological Development was not impaired in patient with SH as compared to euthyroid children.

Page 31: subclinical hypothyrodism

Effects of SCH on Cardiovascular system

• children and adolescents with SCH were found to have significant impairment of diastolic and longitudinal systolic cardiac function on echocardiography

Page 32: subclinical hypothyrodism

Effects of SCH on lipid metabolisim

• A significantly higher concentration of serum total and low-density lipoprotein (LDL) cholesterol was found in children with SCH as compared to euthyroid children

Page 33: subclinical hypothyrodism
Page 34: subclinical hypothyrodism

Management • TSH between 4.5 and 10 mIU/l should be

followed-up.

• TSH > 10 mIU/l with normal FT4 levels may be treated.

• Especially in presence of :1- goiter .2- positive antibodies .3- signs and symptoms.

Page 35: subclinical hypothyrodism

Management

• Start with small dose.• Monitor TFT every 6-8 weeks.• Consider imaging if TSH is

persistently high.

Page 36: subclinical hypothyrodism

conclusion• SH in children seems to be a remitting

process with a low risk of evolution toward overt hypothyroidism.

• The initial presence of goiter and elevated TG-Abs and a progressive increase in TPO-Abs and TSH values predict a progression toward overt hypothyroidism.

Page 37: subclinical hypothyrodism

• Replacement therapy is not justified in children with SH but with TSH 4.5–10 mIU/l, no goiter, and negative antithyroid antibodies

conclusion

Page 38: subclinical hypothyrodism

References 1- Seshadri KG. Subclinical hypothyroidism in

children.Indian J Endocrine Metababolisim 2012;16:S156-8.

2-FRANCESCA CALACIURA . Subclinical Hypothyroidism in Early Childhood:A Frequent Outcome of Transient Neonatal Hyperthyrotropinemia .The Journal of Clinical Endocrinology & Metabolism 87(7):3209–3214

Page 39: subclinical hypothyrodism

References3- M SHRIRAAM AND M SRIDHAR .Subclinical

Hypothyroidism in Children . INDIAN PEDIATRICS .VOLUME 51-NOVEMBER 15, 2015

4- Yardena Tenenbaum-Rakover. Approach to Subclinical Hypothyroidism in Children. http://dx.doi.org/10.5772/5513.2013

5- John Lazarus. 2014 European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children. Eur Thyroid J 2014;3:76–94

Page 40: subclinical hypothyrodism

References

6-Aneta Gawlik. Subclinical Hypothyroidism in Children and Adolescents:Is It Clinically Relevant? International Journal of Endocrinology. 2015.

7-Wasniewska M, Elevated TSH levels normalize or remain unchanged in the majority of children with subclinical hypothyroidism. Eur J Endocrinol 2009;160:417-21.

Page 41: subclinical hypothyrodism

References8- Alice Monzani,Natural history of subclinical

hypothyroidism in children and adolescents and potential effects of replacement therapy: a review. European Journal of Endocrinology (2013) 168 R1–R11

9- Emel Torun1, Subclinical hypothyroidism in obese children .Dicle Medical Journal.2013

Page 42: subclinical hypothyrodism
Page 43: subclinical hypothyrodism